Sign in to view content

Two-Year Real-World Treat and Extend Patterns and Fluid Outcomes Among Neovascular Age-Related Macular Degeneration Patients Treated With Anti-VEGFs

Michael A. Singer, MD

Video
Published 2020

Related

Five-Year Outcomes After Initial Aflibercept, Bevacizumab, or Ranibizumab Treatment for Diabetic Macular Edema (Protocol T)
Dante Joseph Pieramici, MD
Annual Meeting Talks
2020
Real World Experience of Brolucizumab for Persistent Macular Fluid in Neovascular Age-Related Macular Degeneration After Prior Anti-VEGF Treatments
Rehan M. Hussain, MD
Annual Meeting Talks
2021
Longitudinal Total Retinal Fluid Index Assessment in nAMD From the OSPREY Study: A Novel Assessment of Fluid Drying Effect
Sunil Srivastava, MD
On Demand Cases, Courses, and Papers
2020

Category: AMD-Neovascular

See more